Providence Capital Advisors’s Boston Scientific BSX Stock Holding History

Providence Capital Advisors’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.8M	Buy	112,400 +45,300	+68%	+$2.46M	0.73%	52
2026 Q1	$4.21M	Sell	67,100 -500	-0.7%	-$40K	0.69%	61
2025 Q4	$6.45M	Buy	+67,600	New	+$6.63M	1.08%	37
2022 Q1	–	Sell	-96,410	Closed	-$4.09M	–	468
2021 Q4	$4.09M	Buy	96,410 +13,810	+17%	+$580K	1.13%	37
2021 Q3	$3.58M	Buy	+82,600	New	+$3.65M	1.12%	41
2018 Q1	–	Sell	-70,000	Closed	-$1.74M	–	251
2017 Q4	$1.74M	Buy	+70,000	New	+$1.93M	1.34%	28

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Providence Capital Advisors's BSX Position: Q2 2026 in Review

Providence Capital Advisors increased its Boston Scientific (BSX) stake by 68% in Q2 2026, buying an estimated $2.46M and bringing the position to 112,400 shares worth $4.8M. The position accounts for 0.73% of the portfolio, ranked #52.

Providence Capital Advisors first reported a position in BSX in Q4 2017 and has held it in 6 quarters since. The position peaked at $6.45M in Q4 2025. 1,477 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

Providence Capital Advisors held 112,400 shares of Boston Scientific worth $4.8M as of Q2 2026.
Providence Capital Advisors bought 45,300 Boston Scientific shares in Q2 2026, an estimated $2.46M.
Boston Scientific made up 0.73% of Providence Capital Advisors's portfolio in Q2 2026, its #52 holding.
Providence Capital Advisors first reported a position in Boston Scientific in Q4 2017 and has held it in 6 quarters since.
Providence Capital Advisors's Boston Scientific position peaked at $6.45M in Q4 2025.
1,477 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Providence Capital Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.